ZOTANSE8 August 2025

Zota Health Care LImited has informed the Exchange about Investor Presentation

Zota Health Care LImited

August 08, 2025

To, The Manager Listing Department, The National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400051

Dear Sir/Madam,

Trading Symbol: ZOTA

Sub: Investor Presentation

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject we, Zota Health Care Limited are submitting herewith enclosed the Investor Presentation.

This is for your information and record.

Thanking you,

Yours faithfully,

For Zota Health Care Limited

Ashvin Variya (Company Secretary & Compliance Officer) Place: Surat

Encl: a/a

Registered Office: Zota House, 2/896, Hira Modi Street, Sagrampura, Surat-395002 Ph: +91 261 2331601 Email: info@zotahealthcare.com Web: www.zotahealthcare.com

CIN: L24231GJ2000PLC038352

INDIA’S LARGEST PRIVATE GENERIC PHARMACY RETAIL CHAIN

Zota Health Care Limited

Q 1 F Y2 6

Inve s t or Pre s e n tation

Safe Harbour

This presentation has been prepared by the Zota Health Care Limited (the “Company”) only for information purpose to the stakeholders and does not contain any offer or invitation to subscribe the securities of the Company. No offering of securities shall be made except by means of offer documents.

This presentation has been prepared on the basis of information and data available with the Company consider reliable. This presentation may not contain all the information that you may consider material. Any liability in respect of the content of or any omission from this presentation is expressly excluded.

Stakeholders are advised to compare the data provided in the presentation with the full financial results available on the website of the Company as well as on website of NSE.

This presentation contains “forward-looking statements”, including “future oriented financial information” and “financial outlook”. These forward-looking statements are based on management’s current expectations and beliefs and are subject to uncertainty. Actual results may vary from the information contained in this presentation due to changes in government policies, regulations, economics reforms, natural calamities, competition, technology, etc. The company is not under any obligation to provide any update or alter forward looking statements, whether as a result of any new information or future events.

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Company

Overview

Zota Healthcare At a Glance

• Zota Health Care Ltd., a publicly listed company on NSE, has established a

significant footprint in the Indian healthcare sector since its inception in 2000.

Business Verticals

• Headquartered in Surat and employing over 520 dedicated professionals, Zota

Health Care Ltd. has seen significant growth over the years, solidifying its strong

presence in the Indian healthcare market.

• Davaindia, launched in 2017, is a retail generic pharmacy chain that provides quality

generic medicines consisting of 2,000+ SKUs.

• The strategic business model allows Davaindia to be both backward and forward

integrated, ensuring control of the entire product life cycle.

Financial Highlights

(FY25 - Consolidated)

Total Revenue

₹ 29,298 lakhs

Gross Profit

₹ 15,567 lakhs

Gross Merchandise Value

₹ 24,562 lakhs

Davaindia

Domestic

2,000+

SKU’s in Davaindia portfolio

1,745

Operational Davaindia Stores*

4,000+ Products covering major

therapeutic segments 1,050+ Distributors currently, present across India

WHO Recognized

manufacturing partners

Exports

Everyday Herbal Group

30+

Exports markets served

250+ Formulations

manufactured for exports

325 Product approvals received out

of 586 dossiers applications

▪ 56% stake in Everyday Herbal Group strengthens Zota Health Care’s supply chain and product development capabilities

▪ Expands the product portfolio in

the high-revenue over-the-counter (OTC) category

*As of 30th June 2025

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Our Journey

2000

2004

2010

2011 Commenced exports,

Zota Health Care -

Acquired all brand

Inaugurated an export-

Incorporated

names of Sayona

oriented formulations

expanding business to

Medicare via an MOU

manufacturing unit in

African countries

2007 Acquired Mexon Health Care Limited's

trademark and brand, including Health Park

Laboratories and Aaron Biotech divisions

2010

Zota Pharmaceuticals and Atoz Pharmaceuticals

merged with Zota Health Care

Sachin, SEZ

2012

2013

Secured WHO-GMP

approval for the

Acquired trademark

and brand names of

manufacturing unit at SEZ

Redix Lifecare

2014 Obtained regulatory

2017 Received regulatory

approvals from Kenya (PPB)

approval for SEZ plant

and Sri Lanka (CDDA) for

from Tanzania (TFDA)

the Sachin SEZ plant

Listed on NSE - SME

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

2017

2018

Introduced Davaindia, a private

Achieved ₹10+ Cr in Export Sales;

sector generic pharmacy,

through three pilot outlets

& 75+ Davaindia stores

2019

2020 With over 250 outlets, Davaindia became

Opened ~150 Davaindia

the largest and fastest growing private

outlets

sector generic pharmacy chain

Migrated to the Main Board

of NSE

2021

Inception of COCO stores

2023

Total Davaindia stores reaching 600

2022

Davaindia secured its position as India’s largest

private sector generic pharmacy with over 500

locations nationwide

2024 Everyday Herbal Group – 56% stake acquired,

licensed by Khadi and Village Industrial

Commission, Government of India.

2025*

Davaindia Expanded to 1,745 no. of active

stores with COCO 986 & FOFO 759

FOUNDATIONAL STEPS IN

DOMESTIC MARKETING

SETTING UP FORMULATIONS

EXPORT BUSINESS

STRENGTHENING CORE AND

PIONEERING DAVAINDIA

*As of 30th June 2025

Management Profile

K E TAN K U M AR Z O TA

C H A I R M A N A N D

N O N - E X E C U T I V E D I R E C T O R

Total Experience: 38+

• Holds a D-Pharmacy degree

• Won ‘Lifetime Achievement Award’ from DCGI &

the title of ‘Pharma Ratna Asia’.

M O X E S H Z O TA

M A N A G I N G D I R E C T O R

S U J I T PAU L

G r o u p C h i e f E x e c u t i v e O f f i c e r

Total Experience: 10+

Total Experience: 23+

• Holds a Bachelor’s degree in pharmacy & Master’s

• Featured on Times Now and Brand Vision

degree in international marketing & business management, BPP University in UK

• Under his guidance, company has established a

global presence in 30+ countries

• Honored among Asia One's Top 100 Global

leaders

• Last stint was with Reliance Retail as Vice

President and also worked with Apollo Pharmacy, StayHappi, Columbia Asia Hospitals, etc.

H I M AN S H U Z O TA

W H O L E - T I M E D I R E C T O R

K AM L E S H Z O TA

W H O L E - T I M E D I R E C T O R

V I R E N Z O TA

W H O L E - T I M E D I R E C T O R

Total Experience: 30+

Total Experience: 27+

Total Experience: 15+

• Holds a Diploma in Pharmacy degree and a

• Holds a bachelor’s degree in pharmacy

• Holds a bachelor’s degree in Business

Diploma in Computer Application

• Playing a vital role in the planning & implementation of Davaindia project.

• Earlier worked with Torrent Pharma, Unique

Pharmaceuticals Laboratories.

Administration, B.R.C.M. College

• Earlier worked in Franchisee Marketing, where he

gained hands-on experience across various regions of India.

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Company Structure

Procurement in listed entity

Zota Health Care Limited

(Listed entity)

Step down subsidiary

Supplying products at ALP*

Davaindia

(Davaindia Health Mart Limited)

COCO

(COCO# stores)

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Domestic

Export

FOFO

(Sales to FOFO# stores)

*ALP – Arm's length price

Business Verticals

# COCO – Company-Owned Company-Operated

FOFO – Franchisee-Owned Franchisee-Operated

FOFO Sales through Zota Health Care Limited

COCO Sales through Davaindia Health Mart Limited

Business & Industry Overview

Business Verticals

R E V E N U E C O N T R IB U T I O N ( Q 1 F Y 2 6 )

1 . D A V A I N D I A 1 . D A V A I N D I A

Consolidated

• A Retail generic pharmacy chain providing quality generic medicines.

• Focuses only on private-label products in:

Everyday Herbal Group

• Medicinal | OTC | Ayurvedic | Cosmetic and Nutraceutical

• Key emphasis is on chronic therapies and ailments

• One-of-its-kind concept started with 3 pilot stores in 2017

Store variants

02 Company Owned Company Operated (COCO) and Franchisee Owned Franchisee Operated (FOFO)

30% – 90% Savings on medicines as compared to branded counterparts

Large Store Network*

100%

Exports

Domestic

15%

• COCO Stores are large format stores operated through our wholly-

owned subsidiary

• FOFO Stores are operated on an asset-light franchisee model

986 COCO stores 759 FOFO stores

**As of 30th June 2025

private labelled products

2 . D O M E S T I C M A R K E T I N G B U S I N E S S

Davaindia

73%

• Procures

finished dosage

forms

from domestic

formulations

manufactures and market them under own portfolio of brands

• Markets the products across the country to the distributors, which,

in turn, cater to retail pharmacies in their respective districts

1,050+ Distributors currently present across India

4,000+ Products covering major therapeutic segments

WHO Partners with WHO recognized manufacturers

3 . E X P O R T S

• Commenced manufacturing operations in 2010 at Sachin (SEZ) unit • The unit facilitates production of about 250 diverse formulations • Focus on prioritizing product registrations across all countries, with the company retaining ownership of Marketing Authorizations (MAs) and registrations in these regions.

325 Product approvals out of 586 dossiers applications

30+ Countries’ approval mainly in the semi regulated and regulated markets

Growth led by exclusive foreign distribution network and exclusive MA holding

z o t a h e a

t h c a r e . c o m

davaindia.com davaindia.com

d d a a v v a a

i i

n n d d

i i

a a . . c c o o m m

Davaindia - the retail generic pharmacy chain, has a rising prominence in the overall business and is one of the fastest growing retail generic pharmacy chains in India.

4 . E V E R Y D A Y H E R B A L G R O U P

• Zota Health Care’s 56% stake in Everyday Herbal Group demonstrates a strategic move toward backward integration • This integration strengthens the product portfolio, particularly in the over-the-counter (OTC) segment, a key contributor

to revenue

Case Study – Savings on Davaindia margins

Same Tablet with same molecule

Multiple brands selling same medicine consisting of same molecule manufactured by same manufacturers with different brand names

Company marketed by >

Indian Pharma MNC 1

Indian Pharma MNC 2

Davaindia

Tablet / Medicine Name

Rosuvas – 10 mg

Rosubest - 10

Rosuvastatin 10

Molecule

Generic Type

Margins

Rosuvastatin 10mg

Branded Generic

Trade Generic

Generic

Trade Margins % Big Pharma / Promotions %

30% 60%

70% 20%

25-30% 0

Consumer Price for 10 Tablets

₹ 208

₹ 115

₹ 25

Significant savings in margins

High intermediary margins for other companies leading to much higher consumer price vs Davaindia

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Tablet

Telmisartan 40 mg & Hydrochlorothiazide 12.5 mg

Levocarnitine 500 mg

Rabeprazole 40 mg

Aceclofenac 100 mg, Paracetamol 325 mg & Serratiopeptidase 15 mg

Manufacturer

Same Manufacturer

Marketed By

Foreign Pharma MNC

Davaindia

Indian Pharma MNC

Davaindia

Indian Pharma MNC

Davaindia

Indian Pharma MNC

Davaindia

MRP

₹ 187.9

₹ 25.0

₹ 404.95

₹ 82.0

₹ 202.5

₹ 35.0

₹ 147.48

₹ 35.0

Davaindia Quality Medication at Affordable Prices

Same Quality, Affordable Price

Davaindia sells generic medicines manufactured by the same producers as branded medicines. This ensures equivalent quality at a fraction of the cost.

Lower Margins, More Savings

Our business model focuses on maintaining modest margins of 25-30%, compared to other companies who incorporate a huge margin of up to ~90% for intermediaries. This results in more affordable prices for consumers.

Cutting Out Intermediaries

Our direct-to-consumer approach eliminates the traditional pharma supply chain, reducing overall costs, and resulting in significant savings for customers.

Industry update

Total turnover of Pharmaceuticals in India in the fiscal year 2024-25 was $54 bn*

The Indian generic drugs market stood at $26.31bn#in 2024 and is expected to grow at a steady compound annual growth rate (CAGR) of 6.10%#

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Source: *Annual Report Department of Pharmaceuticals FY 24-25, # Research Reports- ModorIntelligence.

DAVAINDIA

Davaindia - Retail Pharmacy Chain data

Revolutionizing the generic pharmacy industry with affordable, accessible, quality healthcare solutions

through retail pharmacies’ chain.

*As of 30th June 2025

2000+

SKUs

1,745*

Total no. of stores

986 COCO stores

759 FOFO Stores

33.35+ lakhs

Quarterly Footfall

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

•

Launched in 2017, Davaindia has rapidly grown into India’s leading private-sector generic pharmacy chain starting with 3 stores and expanded to 1,745 active

stores as of June 2025

Fundamentally driven by providing quality generic medicines at substantial discounts - remarkably 30% to 90% lower than their branded counterparts

Focuses exclusively on private-label products in medicinal, OTC, and ayurvedic categories, with a significant emphasis on chronic therapies and ailments

Every 10 hours, a new davaindia store opens to serve customers better

Every 5 hours, a new employment generation.

2 store Variants

• Company-Owned Company-Operated (COCO)

• Franchisee-Owned Franchisee-Operated (FOFO)

23 States

4 Union Territories

Davaindia - Operating Model

Offers a cluster-based store model, optimizing accessibility and convenience for customers across diverse regions

CLUSTER BASED APPROACH

2,000+ SKUs with 70% medicinal products and 30% OTC products, with a special emphasis on chronic ailments such as cardiac, diabetic and thyroid.

COMPREHENSIVE PORTFOLIO

Cloud-based software and AI-based tools for real-time supply chain and operations management

TECHNOLOGY- BASED MODEL

Implementing a hyperlocal model with on-demand delivery of medicines at consumers’ homes

HYPERLOCAL MODEL

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

COCO MODEL (NEW FORMAT STORES) Large-format, walk-in, Company- Owned Company-Operated stores in key metropolitans & cities across the country

EXCLUSIVE SALE 100% of our product portfolio comprises exclusive sales of private-label generic medicines, OTC, and ayurvedic products

BRAND BUILDING Brand building and consumer- facing advertisement and promotional campaigns with Mr. Kapil Dev as the brand ambassador undertaken by Davaindia

FOFO (Franchisee) MODEL Franchisee-Owned Franchisee-Operated stores adhere to an asset-light model, contributing to scalability and accessibility

Davaindia B2C Online Portal and Mobile App

This e-commerce platform is launched as a hyperlocal model wherein (COCO) retail outlets operated by Davaindia Health Mart Limited, will serve as fulfilment centres ensuring swift and efficient order processing and delivery

z o t a h e a

Davaindia - Eliminating traditional supply chain

By sourcing directly from manufacturers and selling straight to consumers,

traditional pharma supply chain is eliminated & the cost benefits are transferred to the consumer

Average consumer price

t h c a r e . c o m

davaindia.com

Doctors

d a v a

~75% savings on Davaindia medicines as compared to branded counterparts on expenses related to retailers, distributors and marketing.

a . c o m

n d

Traditional Pharma

Manufacturer

Pharma Marketing Company

Distributors

Retailers

Consumers

₹ 100 Traditional Pharma

Davaindia Model

Manufacturer

Consumers

₹ 25 Davaindia

Strengthening the Visibility

Zota Group Welcomes Mr. Suniel Shetty as Brand Ambassador of Davaindia

z o t a h e a

t h c a r e . c o m

Davaindia – What are COCO Stores

COCO stores are modern walk-in stores providing a distinct contrast to traditional counter-based pharmacies enhancing customer satisfaction and loyalty.

Rapid Expansion

& growth

The time required to open a new COCO store has been significantly reduced from 90 days to 75 days, with further plans to reduce it to 60 days. This allows for rapid store expansion and business growth

Profitable

COCO stores have not only been well-received by consumers but have also proven to be more profitable

Smaller Store Size

Average size of a COCO store is 350-500 sq. feet, which is leading to lower rental and maintenance costs. Despite the small size, these stores can offer a wide range of products to cater to different customer needs.

Efficient Inventory Management

With a working capital cycle of 30-40 days, COCO stores can maintain optimal inventory levels, thus reducing storage costs and potential wastage.

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Company-Owned Company-Operated

(COCO)

Davaindia – COCO Stores

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Davaindia - COCO Stores

986

Operational COCO stores

COCO

Company-Owned Company-Operated

Davaindia Health Mart

Operated by wholly-owned subsidiary Davaindia Health Mart Ltd

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

a . c o m

Significant rent rationalization to ₹ 32,000 p.m. in 3rd phase (651 stores) from ₹ 40,000 p.m. in 2nd phase (101 stores) ₹ 82,000 p.m. in 1st phase (100 stores)

n d

✓ Increased cost efficiency

✓ Long-term economic sustainability of

COCO stores

195

107

289

Enhancing Store Economics

States West Bengal Uttar Pradesh Maharashtra Delhi Haryana Kerala Rajasthan Telangana Uttarakhand Karnataka Gujarat Punjab Madhya Pradesh Himachal Pradesh Chhattisgarh Odisha Pondicherry Goa Total

No. of Stores 289 195 107 85 57 57 34 34 34 27 23 22 10 5 2 2 2 1 986

As of 30th June 2025

Davaindia COCO - KPI’s (1/2)

No. of Stores

Quarterly Footfall

986

852

658

494

387

11.8

8.6

in lakhs

23.0

19.0

15.7

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Q1 FY25

Q2 FY25

Q3FY25

Q4FY25

Q1FY26

Q1 FY25

Q2 FY25

Q3 FY25

Q4FY25

Q1FY26

As of 30th June 2025

Davaindia COCO - KPI’s (2/2)

Quarterly GMV

₹ lakhs

Avg. Wallet Spend

₹

₹ 5,290

₹ 238

₹ 4,297

₹ 3,507

₹ 229

₹ 224

₹ 227

₹ 231

₹ 2,714

₹ 2,050

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Q1 FY25

Q2 FY25

Q3 FY25

Q4FY25

Q1FY26

Q1 FY25

Q2 FY25

Q3 FY25

Q4FY25

Q1FY26

Younger COCO Stores to fuel growth

986 Total COCO Stores

265 COCO Stores <5m

Significant Young Store Network

Many of our stores are relatively new, still in the early stages of their lifecycle.

While currently modest in revenue, expected to grow multiple folds as they mature.

Average monthly Sales of matured stores (15+ months) is ~219%

higher than average monthly Sales of younger stores (<3 months)

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

s e a S y h t n o m e g a r e v A

Average monthly Sales by Store age

• Ongoing Expansion: Our strategy includes continuous addition of new stores,

₹ 219

further expanding our reach to newer markets. This will result in an expanded

customer base.

219%

•

Increased Footfall: As young stores mature and new ones are added, we

anticipate an increase in footfall. This will inevitably contribute to higher revenue

₹ 100

generation.

• Anticipated Exponential Growth: As young stores mature and build out their

customer bases, the income is forecasted to multiply. This implies that our

revenues are on a trajectory of exponential growth.

0-3 Months

15 + Months

Store Age Average monthly Sales rebased to ₹100

Store Opening Lifecycle – COCO

Days

00 02 04 06 08 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52 54

58 60

62 64 66 68 70

74 76

75 Days

z o t a h e a

t h c a r e . c o m

Registration

Documentation - Online

Signing process

Store layout Planning

Store Execution Process

Software Installation

Process

Inauguration

davaindia.com

d a v a

n d

c o m

Colour + POP+ Furniture installation

Final Store branding design PPT

Applying Drug Licence & Pharmacist Training

Approval Drug Licence

Initial stock Payment & Dispatch

Software Installation

Receiving stock at store

Inauguration

Same Store Growth – 234 Stores

2.56

1,797

2.97

2,086

3.22

2,258

3.29

2,308

QoQ 4.5%

YoY 34.5% 3.44

2,418

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

c o m

Q1FY25

Q2FY25

Q3FY25

Q4FY25

Q1FY26

Total GMV (₹ lakhs)

Average Per Store Per Month GMV (₹ lakhs)

The average GMV (Gross Merchandise Value) per store per month increased from ₹2.56 lakhs in Q1FY25 to ₹3.44 lakhs in Q1FY26, reflecting a strong growth trajectory driven by improved store-level performance, higher footfall, better product mix, and enhanced operational efficiencies

Same Store Growth: Period-wise Analysis

(36+ Months)

6.56

(24+ Months)

4.28

5.53

Opening Period: 1 Apr 21 - 30 Jun 22

3.67

Number of Stores: 29

19% YoY

Opening Period: 1 Jul 22 - 31 Mar 23

Number of Stores: 54

17% YoY

Jun-24

Jun-25

Jun-24

Jun-25

(15+ Months)

2.98

(12+ Months)

2.34

2.13

Opening Period: 1 Apr 23 - 31 Dec 23

Number of Stores: 52

1.28

40% YoY

Opening Period: 1 Jan 24 - 31 Mar 24

Number of Stores: 99

83% YoY

Jun-24

Jun-25

Jun-24

Jun-25

• Same-store growth reflects strong performance across all periods, with mature stores ensuring stability and newer stores showing rapid

growth momentum

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

c o m

Same Store Growth: Period-wise Analysis

(9 TO 12 Months)

(6 to 9 Months)

1.92

2.05

Opening Period: 1 Apr 24 - 30 Jun 24

1.81

Opening Period: 1 Jul 24 - 30 Sep 24

1.59

Number of Stores: 136

1.30

Number of Stores: 123

1.50

Q-1 (2024-25)

Q-2 (2024-25)

Oct-24

Mar-25

Jun-25

Dec-24

Mar-25

Jun-25

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

c o m

(3 to 6 Months)

1.40

1.20

0.95

(0 TO 3 Months)

1.32

Opening Period: 1 Oct 24 - 31 Dec 24

0.94

Opening Period: 1 Jan 25 - 31 Mar 25

Number of Stores : 164

Q-3 (2024-25)

Number of Stores: 195

Q-4 (2024-25)

Jan-25

Mar-25

Jun-25

Apr-25

Jun-25

Revenue Growth Trajectory of New Stores

1,64,000

1,46,000

1,75,000

1,80,000

1,95,000

2,05,000

2,25,000

1,26,000

1,03,000

76,000

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

c o m

1st Month

2nd Month

3rd Month

4th Month

5th Month

6th Month

7th Month

8th Month

9th Month

10th Month

GMV (₹)

•

A new store's monthly revenue grows significantly from ₹76,000 in Month 1 to ₹2,25,000 by Month 10, showcasing a robust maturation curve

Note: Sale trend basis on the 358 stores which have been opened between Jan 2024 and Sep 2024

Davaindia – What are FOFO Stores

Franchisee-Owned Franchisee-Operated (FOFO)

Asset-light franchise model

FOFO stores employ an asset-light franchise model, contributing to the scalability and accessibility of our product offerings.

Smaller Store size

FOFO stores are compact and over-the-counter format stores, typically having an average size of about 200-300 sq.ft.

Enhancing Customer

Experience:

Walk-In FOFO Stores since Q4FY23

Starting Q4FY23, all newly added Franchisee- Owned Franchisee-Operated (FOFO) stores will be made walk-in, aimed at enhancing the shopping experience by allowing customers to interact and familiarize with the products.

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Davaindia - FOFO Stores

155

133

104

759

Operational FOFO stores

As of 30th June 2025

FOFO

States Uttar Pradesh West Bengal Odisha Madhya Pradesh Gujarat Maharashtra Haryana Delhi Rajasthan Bihar Kerala Tripura Jammu And Kashmir Assam Tamil Nadu Karnataka Uttarakhand Jharkhand Punjab Telangana Arunachal Pradesh Andhra Pradesh Goa Himachal Pradesh Chhattisgarh Daman And Diu Total

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Franchise Owned Franchise Operated

No. of Stores

155 133 104 58 52 40 37 27 27 23 15 15 10 9 9 8 8 7 7 4 3 2 2 2 1 1 759

Davaindia - FOFO Stores

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Davaindia FOFO - KPI’s (1/2)

No. of Stores

Quarterly Footfall

in lakhs

759

730

11.3

10.4

8.9

11.9

12.4

697

664

645

Q1 FY25

Q2 FY25

Q3 FY25

Q4FY25

Q1FY26

Q1 FY25

Q2 FY25

Q3 FY25

Q4 FY25

Q1 FY26

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Davaindia FOFO - KPI’s (2/2)

Quarterly GMV

₹ lakhs

Avg. Wallet Spend

₹

₹ 3,385

₹ 3,488

₹ 290

₹ 3,161

₹ 2,840

₹ 2,608

₹ 285

₹ 281

₹ 279

₹ 274

Q1 FY25

Q2 FY25

Q3 FY25

Q4 FY25

Q1 FY26

Q1 FY25

Q2 FY25

Q3 FY25

Q4 FY25

Q1 FY26

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

OTC Over- the -counter products

Strategic Acquisition as a move towards backward integration

Acquired 56% stake in the Everyday Herbal Group*, licensed by the Khadi and Village Industrial Commission, a strategic move towards backward integration.

~30% SKUs

OTC products make up ~30% of the stock keeping units (SKUs) offered by our company making it an important part of the business

Khadi

MOU with Everyday Herbal Group leverages the REGP license granted by the Government of India, giving additional credibility and leveraging the well-known 'Khadi' mark.

Q1FY26 OTC

Revenue contribution 27%

*Everyday Herbal Beauty Care & Everyday Health And Beauty Care

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

OTC – Products

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Davaindia is Revolutionising the Indian Healthcare Scenario

₹24,562 lacs

~60 %

Gross Merchandise Value in FY25

Gross Margin in COCO format

1,745

30-90 %

Fast growing FOFO & COCO store network*

Savings to consumers on Generic medicines

3.49 Lacs sq. ft*

Total Space Stores

25-30 %

Mature COCO Stores EBITDA#

*As on 30th June 2025

# Calculated prior to IND AS 116

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

State-Wise Presence of Davaindia Across India (COCO & FOFO Models)

States West Bengal Uttar Pradesh Maharashtra Delhi Haryana Kerala Rajasthan Telangana Uttarakhand Karnataka Gujarat Punjab Madhya Pradesh Himachal Pradesh Chhattisgarh Odisha Pondicherry Goa Bihar Tripura Jammu And Kashmir Assam Tamil Nadu Jharkhand Arunachal Pradesh Andhra Pradesh Daman And Diu Total

*As on 30th June 2025

COCO 289 195 107 85 2 57 23 57 10 34 34 34 27 22 - - - - - 5 - 2 1 - 2 - - 986

FOFO 133 155 40 27 104 37 52 15 58 27 8 4 8 7 23 15 10 9 9 2 7 1 2 3 - 2 1 759

Total 422 350 147 112 106 94 75 72 68 61 42 38 35 29 23 15 10 9 9 7 7 3 3 3 2 2 1 1745

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Davaindia Competitive Edge

The USP of Davaindia: Affordable, Trustworthy, and Innovative Pharmacy Solutions

BENEFITS TO THE CUSTOMERS

BENEFITS TO THE FRANCHISEES

Medicines priced at low MRP thereby ensuring affordability for the masses

Store operations and the supply chain efficiently managed by cloud-based software & AI

Private labels offered, helps in building customer trust by ensuring consistency

Widespread marketing activities help in promoting the brand and improving sales

Continuously adding to its product range thereby offering variety

Products procured from WHO & GMP approved plants and quality attested at NABL approved labs

Elimination of distributors ensures timely supply of stock

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Healthy Repeats

Total Average (in %)

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

With a strong base of 80% repeat customers, Davaindia

demonstrates a high level of customer satisfaction and

loyalty.

80%

Repeat Customers

12%

New Customers

08%

Lost Customers

Higher Chronic category share

57%

60%

27%

16%

27%

13%

Chronic

OTC

Other

Chronic

OTC

Other

CATEGORY MIX FY25

CATEGORY MIX Q1FY26

Higher chronic share: A significant 60% of our revenue comes from chronic disease category, signalling high realization and retention rates, reflecting our crucial role in sustaining long-term patient care.

A pronounced emphasis is placed on chronic therapies and ailments such as cardiac, diabetic, thyroid, and neuropsychiatric, resonating with the core healthcare needs of our customers.

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Supply Chain Management

•

The Company has outsourced supply chain management to a third-party warehousing & logistics partner.

• A state-of-art central warehousing & processing center has been built in Surat, in Phase 1.

•

Eventually the Company will replicate such infrastructure across different zones in the country.

Click the link below for more details

Click here

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Domestic Operations

Domestic marketing has been the oldest business vertical for the Company and has

remained its mainstay in the past. Until 2017, this vertical contributed most of the

Company’s revenues. This business vertical distributes generic drugs, OTC products,

and other pharmaceutical products through the Company’s distribution network spread

across India.

1,050+

Distributors spread across India

4,000+

Products in the portfolio

MARKETING VALUE CHAIN

FDF Manufacturers WHO-GMP certified manufacturing partners

Branding Quality check, packaging and branding under the umbrella of Zota brands

Distribution Direct distribution to 1,050+ distributors spread across the country

Retail Pharmacies Ethical marketing, sales distribution and promotional activities undertaken by distributors

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Expor t Operations

Our Exports business vertical, which started in 2010, serves clients in over 30 countries, mainly

in the CIS, Latin America, Africa, and Asia. At its plant in Sachin, SEZ, the Company

manufactures generic formulations for the dossiers it has registered in overseas markets.

At present, the Company has registered over 325 dossiers, while another 261 dossiers have

been filed and are awaiting approval from the relevant regulatory agencies.

250+

325

261

Products manufactured

Dossiers registered

Dossiers pending approval

Countries exported to:

1. Benin 2. Bolivia 3. Cambodia 4. Cameroon 5. Costa Rica 6. Ethiopia 7. Georgia

8. Ivory coast 9. Kenya 10. Mali 11. Myanmar 12. Nepal 13. Nigeria 14. South Africa

15. Sri Lanka 16. Swaziland 17. Tanzania 18. Turkmenistan 19. Uganda 20. Ukraine 21. Uzbekistan

22. Vietnam 23. Zambia 24. Kyrgyzstan 25. Libya 26. Yemen

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Financial

Overview

Management Commentary

“We are pleased to report a strong start to FY26, with Zota Health Care delivering an impressive 84% year-on-year consolidated revenue growth in Q1. This performance was driven by robust demand for affordable generics and our continued efforts to expand access across the country. The growing prevalence of diabetes, cardiovascular diseases and respiratory disorders remains a key driver of demand for cost-effective medicines. Additionally, the rise of e-pharmacies is significantly improving accessibility in remote areas, supporting last-mile delivery and broadening the reach.

During the quarter, we added 163 new stores, including 134 COCO and 29 FOFO outlets. COCO stores grew significantly from 387 to 986 on YoY, strengthening our company-owned infrastructure, while FOFO stores increased from 645 to 759 on YoY, supporting our asset-light expansion strategy. Quarterly footfalls more than doubled to 35.35 lakhs, up from 17.5 lakhs in Q1 FY25, fuelled by our aggressive store expansion strategy and growing brand awareness. To further boost brand visibility and consumer engagement, we appointed renowned actor and entrepreneur Mr. Suniel Shetty as our Brand Ambassador during the quarter. This surge in footfall translated into an 88% increase in (GMV), which rose to ₹8,778 lakhs from ₹4,658 lakhs in the same period last year. Notably, this growth was well-distributed across both COCO and FOFO formats.

Looking ahead, we remain committed to sustaining this momentum by deepening our national footprint and enhancing store-level efficiencies. Our growth strategy is well-aligned with the evolving trends in the Indian generics market, and we are well-positioned to capitalize on the rising demand for affordable, high-quality medicines across the country”

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Mr. Ketankumar Zota Chairman

Quar terly Revenue Segmentation

Business Verticals – Consolidated Revenue bifurcation

Davaindia

₹ lakhs

Domestic Operations

₹ lakhs

Export Operations

₹ lakhs

Everyday Herbal

₹ lakhs

7,563

6,282

1,771

1,391

1,507

1,234

624

441

3,581

664

472

186

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Q1 FY25 Q4 FY25 Q1 FY26

Annually Financial Snapshot

Davaindia has driven revenue growth, recording an impressive increase of ~ 65% CAGR since FY22.

Business Verticals – Consolidated Revenue bifurcation

Davaindia

₹ lakhs

18,621

10,356

5,578

4,122

Domestic Operations

₹ lakhs

Export Operations

₹ lakhs

6,342

5,983

5,950

5,689

3,014

3,190

2,467

2,004

FY22

FY23

FY24

FY25

FY22

FY23

FY24

FY25

FY22

FY23

FY24

FY25

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Business Ver tical Performance ( C o n s o l i d a t e d )

₹ in lakhs

Particulars

Revenue from Operation

Cost of Goods Sold

Gross Profit

% Margin

Employee cost

Other expenses

Operational Expenses

Operating Profit ( Pre IND AS)

% Margin

Other Income

EBITDA (Pre IND AS)

% Margin

Q1 FY26

Business Vertical

Davaindia

Domestic

Exports

Everyday

7562.9

2807.1

4755.8

62.9%

2934.4

2770.9

5705.3

-949.5

-13%

72.20

-949.5

-13%

1506.9

1009.6

497.3

33.0%

145.5

271.2

416.7

80.6

17.0

97.6

664.2

343.9

320.3

48.2%

165.0

100.4

265.4

54.9

-1.6

53.2

624.4

352.7

271.7

43.5%

72.4

28.5

100.9

170.8

27%

0.3

171.1

27%

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

(Consolidated)

Consolidated

10358.4

4513.3

5845.0

56%

3317.3

3171.0

6488.3

(643.2)

-6%

87.6

(627.6)

-5%

Profit & Loss Statement ( C o n s o l i d a t e d )

₹ in lakhs

Particulars

Export Sales (SEZ)

Davaindia Sales

Domestic Sales

Everyday Herbal Group

Revenues from Operations

Cost of Goods Sold

Gross Profit

% Margin

Employee cost

Other expenses

Operational Exp

Operating Profit

% Margin

Other Income

EBITDA

% Margin

Depreciation

EBIT

Interest Cost

EBT

Taxes

Profit After Taxes

Q1FY26

664.2

7,562.9

1,506.9

624.4

10,358.3

4,513.3

5,845.1

56.4%

3,317.3

2,132.0

5,449.3

395.7

3.8%

87.6

483.4

4.7%

1,467.8

-984.5

323.9

-1,308.4

69.4

-1,377.8

Q4FY25

Q1FY25

1,233.7

6,281.7

1,771.1

441.0

9,727.5

4,787.5

4,940.0

50.8%

2,593.6

2,099.7

4,693.3

246.7

2.5%

100.2

346.8

3.6%

1,431.5

-1,084.7

345.8

-1,430.5

-141.6

-1,288.9

472.1

3,580.9

1,390.9

186.3 5,630.2

2,634.1

2,996.1

53.2%

1,624.7

1,497.2

3,121.9

-125.8

-2.2%

1.8

-124.0

-2.2%

802.4

-926.3

289.8

-1,216.13

56.1

-1,272.27

FY25

3,190.3

18,621.4

6,341.5

1,144.2

29,297.5

13,730.3

15,567.1

53.1%

8,606.6

7,533.8

16,140.4

-573.3

-1.96%

206.8

-366.5

-1.3%

4,319.6

-4,686.1

1,078.3

-5,764.5

90.5

-5,855.0

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

(Consolidated)

FY24

2,003.5

10,355.9

5,689.4

18,048.9

9,670.0

8,378.8

46.4%

3045.1

4578.4

7623.4

755.4

4.2%

115.6

871.0

4.8%

2008.5

-1137.5

478.8

-1616.3

-181.5

-1434.8

Thank You

C o n t a c t I n f o r m a t i o n

M r . A s h v i n V a r i y a

" Z O T A H O U S E " , 2 / 8 9 6 , H i r a M o d i S t r e e t , S a g r a m p u r a , S u r a t - 3 9 5 0 0 2 ( G u j a r a t )

c s z o t a @ z o t a h e a l t h c a r e . c o m w w w . z o t a h e a l t h c a r e . c o m

E Y L L P

S i d d e s h C h a w a n - s i d d e s h . c h a w a n @ i n . e y . c o m

A j i t M i s h r a - a j i t . j . m i s h r a @ i n . e y . c o m

w w w . e y . c o m

← All Transcripts ZOTA Stock Page →

Zota Health Care LImited has informed the Exchange about Investor Presentation

Market Movers